

Accepted Manuscript

Tumefactive multiple sclerosis lesions associated with fingolimod treatment: report of 5 cases

Pedro Sánchez , Virginia Meca-Lallana , José Vivancos

PII: S2211-0348(18)30199-8
DOI: [10.1016/j.msard.2018.07.001](https://doi.org/10.1016/j.msard.2018.07.001)
Reference: MSARD 876



To appear in: *Multiple Sclerosis and Related Disorders*

Received date: 17 April 2018
Revised date: 17 May 2018
Accepted date: 1 July 2018

Please cite this article as: Pedro Sánchez , Virginia Meca-Lallana , José Vivancos , Tumefactive multiple sclerosis lesions associated with fingolimod treatment: report of 5 cases, *Multiple Sclerosis and Related Disorders* (2018), doi: [10.1016/j.msard.2018.07.001](https://doi.org/10.1016/j.msard.2018.07.001)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Highlights

- Fingolimod can be associated with tumefactive lesions in predisposed patients.
- Fingolimod withdrawal may be associated with rebound and development of tumefactive lesions.
- Close monitoring of these patients after stopping fingolimod is advisable.

Download English Version:

<https://daneshyari.com/en/article/8647269>

Download Persian Version:

<https://daneshyari.com/article/8647269>

[Daneshyari.com](https://daneshyari.com)